Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma an Open-label,Phase 1 Study.
Phase of Trial: Phase I/II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Donafenib (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 17 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 17 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 17 Oct 2017 Status changed from not yet recruiting to recruiting.